INNOVIVA, INC. Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs
INNOVIVA, INC. (INVA) had Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs of $9.16 million as of 2021-12-31, per its 10-K/A filed 2022-03-17.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities
us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts · last filed 2022-03-17
- 2021-12-31: Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs $9.16M.
- 2020-12-31: Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs $10.60M.
- 2019-12-31: Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs $11.95M.
- 2018-12-31: Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs $13.12M.
| Period end | Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs |
|---|---|
| 2021-12-31 | $9.16M 10-K/A · filed 2022-03-17 |
| 2020-12-31 | $10.60M 10-K/A · filed 2022-03-17 |
| 2019-12-31 | $11.95M 10-K · filed 2021-02-25 |
| 2018-12-31 | $13.12M 10-K · filed 2020-02-19 |
| 2017-12-31 | $14.00M 10-K · filed 2019-02-19 |
| 2016-12-31 | $0.00 10-K · filed 2018-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |